(±)-Enitociclib (Standard)

Overview

(±)-Enitociclib (Standard) is the analytical standard of (±)-Enitociclib ( HY-103019A ). This product is intended for research and analytical applications. (±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer . Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib ( HY-10227 ) and Lenalidomide ( HY-A0003 ), and can be used in the research of hematological malignancies.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > CDK | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-103019AR
• CAS No.: 1610358-53-6
• Molecular Formula: C19H18F2N4O2S
• Molecular Weight: 404.43
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source